UiPath (NYSE:PATH) Shares Down 1.6%

UiPath Inc. (NYSE:PATHGet Free Report)’s share price fell 1.6% on Thursday . The stock traded as low as $19.16 and last traded at $19.27. 2,123,128 shares traded hands during trading, a decline of 73% from the average session volume of 7,989,241 shares. The stock had previously closed at $19.59.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PATH. BMO Capital Markets boosted their price objective on UiPath from $24.00 to $28.00 and gave the company a “market perform” rating in a report on Thursday, March 14th. Barclays raised their target price on UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday, March 15th. Truist Financial reaffirmed a “buy” rating and set a $32.00 target price on shares of UiPath in a report on Wednesday, March 20th. DA Davidson raised their target price on UiPath from $20.00 to $24.00 and gave the stock a “neutral” rating in a report on Thursday, March 14th. Finally, Wells Fargo & Company increased their price target on UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $27.41.

Check Out Our Latest Stock Report on UiPath

UiPath Stock Down 0.3 %

The stock has a market cap of $10.80 billion, a PE ratio of -111.64 and a beta of 1.01. The stock has a 50-day moving average of $20.63 and a 200 day moving average of $22.06.

UiPath (NYSE:PATHGet Free Report) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million during the quarter, compared to analysts’ expectations of $383.32 million. Research analysts forecast that UiPath Inc. will post -0.04 EPS for the current fiscal year.

Insider Activity

In related news, CFO Ashim Gupta sold 16,000 shares of UiPath stock in a transaction on Friday, March 15th. The stock was sold at an average price of $22.84, for a total value of $365,440.00. Following the completion of the transaction, the chief financial officer now directly owns 87,505 shares in the company, valued at $1,998,614.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 96,000 shares of company stock valued at $2,023,440. 22.37% of the stock is currently owned by corporate insiders.

Institutional Trading of UiPath

A number of institutional investors have recently bought and sold shares of PATH. Royal London Asset Management Ltd. increased its position in UiPath by 5.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after acquiring an additional 7,742 shares during the period. Swiss National Bank lifted its stake in UiPath by 4.9% in the 4th quarter. Swiss National Bank now owns 1,211,500 shares of the healthcare company’s stock valued at $30,094,000 after buying an additional 56,600 shares in the last quarter. Vestmark Advisory Solutions Inc. purchased a new stake in UiPath in the 4th quarter valued at approximately $15,543,000. O Shaughnessy Asset Management LLC purchased a new stake in UiPath in the 3rd quarter valued at approximately $203,000. Finally, Invesco Ltd. lifted its stake in UiPath by 2.8% in the 3rd quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock valued at $6,830,000 after buying an additional 10,863 shares in the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Company Profile

(Get Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

See Also

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.